REG - Cambridge Nutrition. - Trading & Business Update

Cambridge Nutritional SciencesAnnouncement

22/04/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260422:nRSV3731Ba&default-theme=true

RNS Number : 3731B  Cambridge Nutritional Sciences PLC  22 April 2026

Cambridge Nutritional Sciences plc

 

(the "Company" or "CNSL")

 

Trading & Business Update

 

Cambridge Nutritional Sciences plc (AIM: CNSL), the specialist medical
diagnostics company focused on promoting a personalised and functional
approach to health and nutrition, is pleased to announce an update on the
Company's trading for the year ended 31 March 2026, ahead of the release of
its audited final results in July 2026.

 

Highlights:

 

·      Total Revenue expected to be £7.0m (2025: £8.3m)

·      Gross profit margin of 67.8% (2025: 65.3%)

·      Adjusted EBITDA** expected to show loss of £0.4m (2025: profit
of £0.4m)

·      Net cash balance of £2.6m (2025: £4.9m)

**Adjusted for exceptional items and share based payment charges

 

2026 financial performance:

 

Revenue was in line with market expectations after adjusting for reduced and
delayed orders from the Middle East & Asia in the second half of the year.
These were driven by a challenging and disrupted trading environment created
by geopolitical instability and uncertainty, rather than a loss of local
business partners. After adjusting for the impacted regions for the full year,
underlying year on year revenue growth was approximately 11%.

 

Despite these revenue challenges, a continued focus on efficiencies and cost
control across the business has resulted in a strong gross margin of 67.8% as
well as an EBITDA loss of only £0.4m (vs £0.4m profit in 2025).

 

James Cooper, CEO, commented:

 

"I am pleased that underlying revenue adjusting for the economic disruption
showed 11% growth; driven in particular by the UK and Indian markets, however
we remain mindful of the potential for ongoing global uncertainties.

 

We continue to drive manufacturing efficiencies and are pleased to report a
gross margin increase to 67.8%. This is a testament to all the hard work of my
colleagues.

 

We are continuing to successfully progress our IVDR development programme
following our heavy investment in capital equipment this year, which we
believe will deliver significant product, cost and market position advantages
to the Company for years to come.

 

I look forward to updating the market further at our results in July 2026."

 

The information communicated in this announcement is inside information for
the purposes of Article 7 of EU Regulation 596/2014

 

 

Contacts:

 

 Cambridge Nutritional Sciences plc                  www.cnsplc.com (http://www.cnsplc.com)
 Carolyn Rand, Non-Executive Chair                   investors@cnsplc.com (mailto:investors@cnsplc.com)
 James Cooper, Chief Executive Officer
 Ajay Patel, Chief Financial Officer

 Cavendish Capital Markets Limited                   Tel: 020 7220 0500
 Geoff Nash / Edward Whiley / (Corporate Finance)
 Nigel Birks / Harriet Ward (ECM)

About Cambridge Nutritional Sciences plc

Cambridge Nutritional Sciences plc (AIM: CNSL) is a specialist medical
diagnostics company focused on promoting a personalised and functional
approach to health and nutrition.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTEFLFLQZLEBBK



            Copyright 2019 Regulatory News Service, all rights reserved